Boston Scientific

11,197

$38.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.52 (+1.39%) Today
+$0.16 (+0.42%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell BSX and other stocks, options, ETFs, and crypto commission-free!

About BSX

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. Read More The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Employees
36,000
Headquarters
Marlborough, Massachusetts
Founded
1979
Market Cap
53.16B
Price-Earnings Ratio
12.52
Dividend Yield
Average Volume
13.94M
High Today
$38.04
Low Today
$36.71
Open Price
$37.48
Volume
10.06M
52 Week High
$46.62
52 Week Low
$24.10

Collections

BSX News

ReutersMay 29

BRIEF-Boston Scientific Says Entered Into Second Amendment To $1 Billion 364-Day Term Loan Credit Agreement

May 29 (Reuters) - Boston Scientific Corp: * BOSTON SCIENTIFIC - ON MAY 28 ENTERED INTO SECOND AMENDMENT TO ITS $1 BILLION 364-DAY TERM LOAN CREDIT AGREEMENT
14
BenzingaMay 27

Boston Scientific Completes Approximately $2.0 Billion Aggregate Offerings of Common Stock and Mandatory Convertible Preferred Stock

MARLBOROUGH, Mass., May 27, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) completed the concurrent offerings of (i) 29,382,500 shares of its com
4

BSX Earnings

$0.00
$0.15
$0.31
$0.46
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
per share
Actual
Expected Jul 22, Pre-Market

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.